Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

57.38 +0.27 (+0.47%)
Streaming Delayed Price Updated: 10:21 AM EST, Feb 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
35 36 Next >
News headline image
Roche Misses Out On Weight-Loss Blockbuster Drug, Now Playing Catch-Up In Booming Market ↗
Roche missed out on acquiring a potential blockbuster weight-loss drug, now owned by Eli Lilly, in 2018. The drug, orforglipron, is projected to generate up to $14 billion annually by 2032, while... 
Via Benzinga
News headline image
Why Is Small-Cap Tempest Therapeutics Stock Trading Higher On Thursday? ↗
Tempest Therapeutics receives FDA feedback on the Phase 3 trial design for amezalpat (TPST-1120) in combination with Tecentriq and Avastin to treat first-line hepatocellular carcinoma. Study to begin... 
Via Benzinga
News headline image
Prediction: This Company Will Disrupt Eli Lilly and Novo Nordisk in the Weight Loss Market (Hint: It's Not Pfizer) ↗
There are a number of pharmaceutical companies looking to make waves in the weight loss market. 
Via The Motley Fool
News headline image
Cancer-Focused Syros Pharmaceuticals Stops Mid-Stage Leukemia Combo Therapy Study, Cites Disappointing Unexpected Outcome ↗
Syros Pharmaceuticals announces discontinuing enrollment in the SELECT-AML-1 Phase 2 trial due to the low probability of demonstrating superiority. The trial evaluated tamibarotene with venetoclax and... 
Via Benzinga
News headline image
Merck Stops Lung Cancer Study For Keytruda Combo Due To Ineffective Results, Side Effects ↗
Merck discontinues the Phase 3 KeyVibe-008 trial for the fixed-dose combination of vibostolimab and Keytruda in extensive-stage small cell lung cancer due to futility in overall survival and increased... 
Via Benzinga
News headline image
Here's Why Eli Lilly Stock Dropped 12% Last Month ↗
News from a competitor gave investors an unwelcome dose of reality. 
Via The Motley Fool
News headline image
Roche Considers Selling Cancer Data Specialist Flatiron Health Business, Highlights Challenges With Start-Up Acquisitions ↗
Roche considers divesting Flatiron Health, acquired for $1.9 billion in 2018, highlighting the challenges big pharma faces with start-up investments. Flatiron's data aids Roche's oncology R&D despite... 
Via Benzinga
News headline image
Bristol Myers Squibb Terminates Cancer Drug Development Program With Agenus ↗
Agenus reports that Bristol Myers Squibb (NYSE: BMY) is ending their 2021 agreement, returning the TIGIT bispecific antibody AGEN1777. This decision is part of Bristol Myers' broader pipeline strategy... 
Via Benzinga
News headline image
Are Eli Lilly and Novo Nordisk Too Expensive For You? Here Are 4 Other Potential Weight Loss Stocks You May Want to Consider Right Now. ↗
The popularity surrounding weight loss drugs such as Mounjaro and Ozempic has brought Eli Lilly and Novo Nordisk newfound growth. 
Via The Motley Fool
News headline image
Weight Loss Drug Stocks Just Took a Hit. Should You Buy the Stock That Caused It? ↗
Roche's latest breakthrough could be a game changer, but it's still too early to say. 
Via The Motley Fool
News headline image
Novo Nordisk's Stock Dips In Pre-Market Despite Winning UK's Approval Of Weight Loss Drug: What's Going On ↗
Wegovy, a GLP-1 receptor agonist, had previously been approved for use in obesity treatment and weight management. 
Via Benzinga
News headline image
Look Out, Eli Lilly and Novo Nordisk: Could Roche Be the Obesity Drug Stock to Really Watch? ↗
Roche might give Lilly and Novo Nordisk a run for their money -- sometime down the road. 
Via The Motley Fool
News headline image
Oral Weight Loss Drugs Vs. Injections - Pills Are Promising Yet Challenging Frontier ↗
Pharmaceutical giants like Roche, Eli Lilly, Novo Nordisk, and Pfizer are racing to develop oral weight loss medications. These drugs promise to complement existing injectables, offering new hope in... 
Via Benzinga
News headline image
This Big Pharma Could Become a Leading Weight-Loss Stock. Should You Buy It? ↗
This company hasn't made its debut on the weight-loss market yet, but it may. 
Via The Motley Fool
News headline image
Better Dark Horse Weight Loss Drug Stock: Pfizer vs. Roche ↗
Neither is a leader right now, but one of them might be on track to change that. 
Via The Motley Fool
News headline image
Stock Market Rotation Gets Rough; ASML, Eli Lilly, CrowdStrike, UnitedHealth In Focus: Weekly Review ↗
The Nasdaq tumbled amid chip woes. 
Via Investor's Business Daily
News headline image
EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players' ↗
Eli Lilly and Novo Nordisk face selloff as new weight-loss drugs threaten dominance. Shares of both companies drop significantly, highlighting need for diversification in this industry. 
Via Benzinga
News headline image
VIX Stages Double-Digit Spike As Risk Off Takes Over; Chipmakers Fail To Rebound, Weight Loss Giants Eli Lilly, Novo Tumble: What's Driving Markets Thursday? ↗
It’s another risk-off day on Wall Street, with all major U.S. indices trading in the red. The CBOE Volatility Index (VIX), often referred to as the market’s fear gauge, spiked over 10%, reaching levels... 
Via Benzinga
Topics Stocks
News headline image
New Data for Genentech’s Susvimo Demonstrates Sustained Efficacy in Two Serious Diabetic Eye Conditions
From Genentech
Via Business Wire
News headline image
Why Roche Stock Just Popped, but Eli Lilly and Novo Nordisk Dropped ↗
Roche has a new GLP-1 weight loss drug in the works -- and one very cheap stock. 
Via The Motley Fool
News headline image
Genentech’s Vabysmo Showed Extended Durability, Continued Efficacy and a Consistent Safety Profile in Long-Term Diabetic Macular Edema (DME) Study
From Genentech
Via Business Wire
News headline image
Pfizer And Roche Advance On Their Weight Loss Drug Journeys ↗
After previously discounting a twice-daily version of its weight loss drug due to patients having difficulties tolerating it, Pfizer Inc (NYSE: PFE) moved forward with the once-daily version. On... 
Via Benzinga
News headline image
Obesity-Drugs Focused Stocks Tumble On Wednesday - What's Going On With Eli Lilly, Novo Nordisk, Viking Therapeutics, Structure Therapeutics? ↗
Eli Lilly, Novo Nordisk, Viking Therapeutics, and Structure Therapeutics shares are down following Roche's promising CT-996 trial results for type 2 diabetes and obesity. Get insights into the latest... 
Via Benzinga
News headline image
Roche Highlights Encouraging Data From Newly-Acquired Second Weight Loss Drug Candidate In Early-Stage Study ↗
Roche reported promising topline results from a Phase 1 trial of CT-996, an oral GLP-1 receptor agonist for type 2 diabetes and obesity. Participants experienced a mean weight loss of 6.1% in four... 
Via Benzinga
News headline image
Genentech Announces Positive Phase I Results of Its Oral GLP-1 Receptor Agonist CT-996 for the Treatment of People With Obesity
From Genentech
Via Business Wire
News headline image
Genentech to Reintroduce Susvimo for People With Wet Age-related Macular Degeneration (AMD)
From Genentech
Via Business Wire
News headline image
3 Small-Cap Stocks With Explosive 2X Growth Potential ↗
Discover three top high-growth small-cap stocks, fueled by potential rate cuts and promising prospects in the second half of 2024. 
Via InvestorPlace
News headline image
Roche's New Immunotherapy Fails To Show Benefit Over Merck's Blockbuster Keytruda In Lung Cancer Patients ↗
Roche's SKYSCRAPER-06 study of tiragolumab plus Tecentriq and chemotherapy did not meet primary endpoints for progression-free survival and overall survival in advanced non-squamous non-small cell lung... 
Via Benzinga
News headline image
FDA Approves Genentech’s Vabysmo Prefilled Syringe (PFS) for Three Leading Causes of Vision Loss
From Genentech
Via Business Wire
News headline image
Genentech Provides Update on Phase II/III SKYSCRAPER-06 Study in Metastatic Non-Squamous Non-Small Cell Lung Cancer
From Genentech
Via Business Wire
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
35 36 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.